Goldfinch acquires global rights to Takeda’s monoclonal antibody

US-based clinical-stage biotechnology company Goldfinch Bio has entered an agreement with Japanese firm Takeda Pharmaceutical for global rights to a preclinical, peripherally restricted cannabinoid receptor 1 (CB1) monoclonal antibody. Under the agreement, the company will assume the development and commercialisation responsibilities for the treatment of metabolic kidney diseases worldwide. Takeda will have the option to ask Goldfinch Bio to negotiate the sub-licensing of Japanese rights to Takeda before the initiation of pivotal studies. Goldfinch, built on a platform designed to identify kidney-specific targets, combines genomic, transcriptomic, proteomic and clinical data. The company plans to use the platform to identify the subsets of kidney disease patients most likely to respond to the therapy.